3-Drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication

Journal of Infectious Diseases

Volumn 197, Issue 1, 2008, Pages 42-45

  Grünberger, Christian ^a   Wyles, David L ^a,b   Kaihara, Kelly A ^a   Schooley, Robert T ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MC 0711 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYLADENOSINE; BENZOFURAN DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; CILUPREVIR; NONNUCLEOSIDE INHIBITOR; NUCLEOSIDE DERIVATIVE; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; SMALL MOLECULAR INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG COMBINATION; HEPATITIS C; HEPATITIS C VIRUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DRUG SYNERGISM; HEPACIVIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; VIRUS REPLICATION;

EID: 39249085992     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/524062     Document Type: Article

References (16)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
2. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-92.
3. Reesink HW, Zeuzem S, Weegink CJ, et al. Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 2005; 42(Suppl 1):234A-5A.
4. Roberts S, Cooksley G, Dore G, et al. Results of a phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology 2006; 44(Suppl 1):692A.
5. Sarrazin C, Kieffer T, Bartels D, et al. Characterization of viral variants in the HCV NS3 protease domain of genotype 1 patients that are selected during 14 days of dosing with VX-950. Hepatology 2005; 42(Suppl 1):751A.
6. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. Top HIV Med 2006; 14:827-43.
7. Hartshorn KL, Vogt MW, Chou TC, et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother 1987; 31:168-72.
8. Johnson VA, Barlow MA, Merrill DP, Chou TC, Hirsch MS. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis 1990; 161:1059-67.
9. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-9.
10. Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol 2007; 81:3005-8.
11. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75:8516-23.
12. Tanabe Y, Sakamoto N, Enomoto N, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α. J Infect Dis 2004; 189:1129-39.
13. Saha AK, Burns CJ, Del Vecchio AM, et al. inventors; Viropharma, assignee. Benzofuran compounds, compositions and methods and treatment and prophylaxis of hepatitis C viral infections and associated diseases. US Patent 60,515,944, filed 30 October 2003 and issued 11 February 2004.
14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
15. Kurosaki M, Enomoto N, Marumo F, Sato C. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology 1994; 205:161-9.
16. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.